Navigation Links
InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application
Date:5/4/2010

BRISBANE, Calif., May 4 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that the U.S. Food and Drug Administration (FDA) issued a complete response letter for the New Drug Application (NDA) for Esbriet™ (pirfenidone) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce decline in lung function.

A complete response letter is issued by the FDA's Center for Drug Evaluation and Research when the review of an application is completed, but there are one or more reasons that preclude the approval of the NDA at this time.  The FDA has requested an additional clinical trial to support the efficacy of Esbriet in IPF patients.  InterMune intends to meet with the FDA as soon as possible to explore the best ways to address the points raised by the Agency and to discuss pathways to approval.  

"After the positive FDA Advisory Committee meeting of March 9 at which the Committee recommended the approval of the pirfenidone NDA by a 9-3 margin, we are disappointed by this outcome," said Dan Welch, Chairman, Chief Executive Officer and President of InterMune.  "We will meet with the FDA as soon as possible to understand their points of view and to determine the most appropriate path forward to expeditiously make Esbriet available to the approximately 100,000 patients with IPF and their families who suffer from this terrible disease and for whom no FDA-approved medicines exist."

Status of Esbriet (pirfenidone) in Europe

On March 2, 2010, InterMune announced that it h
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. InterMune to Release First Quarter Financial Results on April 29
2. InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF
3. InterMune Announces Proposed Public Offering of Common Stock
4. InterMune to Release Third Quarter Financial Results on November 5
5. InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis
6. InterMune to Present at Canaccord Adams Conference
7. InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
8. InterMune to Release Second Quarter Financial Results on August 6
9. InterMune to Present at Goldman Sachs Healthcare Conference
10. InterMune Reports First Quarter 2009 Financial Results and Business Highlights
11. InterMune to Release First Quarter Financial Results on April 30
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... DALLAS and NEW YORK , ... a biopharmaceutical company advancing patient care in critical areas, announced ... of common stock, and warrants to purchase up to an ... of $4.00 per share and $.01 per warrant.  The warrants ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market ... (Columns, Solvents, Buffers, Valves, Guages, Seals), Accessories, Services, ... Forecasts to 2019” provides a detailed overview of ... trends, and strategies impacting the preparative and process ...
(Date:12/24/2014)... SoundConnect’s 2015 next ... edge communication technology, provide continued education and inform ... series demonstrates online communication features and benefits; empowering ... most innovative and powerful tools. , According to ...
(Date:12/24/2014)... The report provides basic information on ... and industry overview. This report also presents product ... is separated by regions, technology and applications. The ... client survey, marketing channels, industry development trend and ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... University researchers are finding ways to improve infrared photodetector ... systems, as well as used increasingly in commercial applications ... in a recent article in the journal ... how infrared photodetection can be done more effectively by ...
... LEXINGTON, Mass., Feb. 14, 2012 Avaxia Biologics, ... drugs that act locally within the gastrointestinal tract, ... million Series A angel-led financing.  Cherrystone Angels of ... from Beacon Angels, Boston Harbor Angels, Launchpad Venture ...
... PROVIDENCE, R.I., Feb. 14, 2012  Nabsys, Inc., a ... positional sequencing technology, today announced that data demonstrating ... DNA will be presented at the annual Advances ... 15 to 18, on Marco Island, Fla., and ...
Cached Biology Technology:New nano-material combinations produce leap in infrared technology 2New nano-material combinations produce leap in infrared technology 3Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease 2Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease 3Nabsys to Present DNA Sequence Data from Solid-State Nanodetectors at the Annual Advances in Genome Biology and Technology (AGBT) Meeting and the EMBL Omics and Personalized Health Conference 2Nabsys to Present DNA Sequence Data from Solid-State Nanodetectors at the Annual Advances in Genome Biology and Technology (AGBT) Meeting and the EMBL Omics and Personalized Health Conference 3
(Date:1/22/2015)... Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), ... general the State of Washington,s Department ... new enrollment and central issuance system for driver,s licenses and ... The project planning and development will start in January 2015, ...
(Date:1/22/2015)... Showcase, Hall E -   EyeLock Inc. , a market ... showcase its EyeLock ID technology integrated in a 3D printed ... Oak Ridge National Laboratory (ORNL) at the 2015 ... technology is being used to validate the driver and authorize ...
(Date:1/22/2015)... , Jan. 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... commerce market, reports on the recent success of the Wocket™ smart wallet ... Wocket smart wallet was named as one of the "11 Hot ... "5 Best Products Launched At CES So Far" by Newseveryday.com and "The ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
... Restoration International (SER) released its May 2008 Briefing ... & Biological Conservation within the Ecosystem Approach at ... the Parties held in Bonn, Germany, May 19-30, ... Ecosystem Approach, as developed by the CBD and ...
... and Technology (NIST) have reported* a new technique to ... centrifuges. Many potential applications for carbon nanotubes depend on ... the most important features of the new technique, say ... to produce industrial quantities of high-quality nanotubes. ...
... of shipments involving regulated radioactive materials used in medicine ... industry experts. Meeting in Rome this week at an ... the Mediterranean region that seeks to ease hardships for ... delivery of beneficial radiation sources. The shipment issues ...
Cached Biology News:Integrating restoration and conservation within the ecosystem approach 2Spin control: New technique sorts nanotubes by length 2Experts tackle shipment issues for beneficial radiation sources 2Experts tackle shipment issues for beneficial radiation sources 3
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
TXNL2 Antibody...
Rat polyclonal to Vitamin B3 ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule, Vitamin B3 conjugated to BSA....
Biology Products: